135 related articles for article (PubMed ID: 9828582)
1. Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery.
Saunders ME; Grant RE
J Natl Med Assoc; 1998 Nov; 90(11):677-80. PubMed ID: 9828582
[TBL] [Abstract][Full Text] [Related]
2. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
[TBL] [Abstract][Full Text] [Related]
3. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery.
Hawkins DW; Langley PC; Krueger KP
Clin Ther; 1998; 20(1):182-95. PubMed ID: 9522114
[TBL] [Abstract][Full Text] [Related]
4. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
Garcia-Zozaya I
J Ky Med Assoc; 1998 Apr; 96(4):143-8. PubMed ID: 9577110
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
O'Brien BJ; Anderson DR; Goeree R
CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
[TBL] [Abstract][Full Text] [Related]
6. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
Dunn CJ; Goa KL
Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
Menzin J; Colditz GA; Regan MM; Richner RE; Oster G
Arch Intern Med; 1995 Apr; 155(7):757-64. PubMed ID: 7695464
[TBL] [Abstract][Full Text] [Related]
8. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement.
Hawkins DW; Langley PC; Krueger KP
Am J Health Syst Pharm; 1997 May; 54(10):1185-90. PubMed ID: 9161627
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
11. Consortium data: comparative efficacy of low molecular weight heparin and warfarin following total hip replacement.
Colwell CW
Orthopedics; 1995 Jul; 18 Suppl():21-3. PubMed ID: 7479422
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement.
Bergqvist D; Jönsson B
Haemostasis; 2000; 30 Suppl 2():130-5; discussion 128-9. PubMed ID: 11251357
[TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
McCullagh L; Tilson L; Walsh C; Barry M
Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
Bala A; Murasko MJ; Burk DR; Huddleston JI; Goodman SB; Maloney WJ; Amanatullah DF
Hip Int; 2020 Sep; 30(5):564-571. PubMed ID: 30990095
[TBL] [Abstract][Full Text] [Related]
15. Are factor Xa inhibitors effective thromboprophylaxis following hip fracture surgery?: A large national database study.
Campbell ST; Bala A; Jiang SY; Gardner MJ; Bishop JA
Injury; 2017 Dec; 48(12):2768-2772. PubMed ID: 29102371
[TBL] [Abstract][Full Text] [Related]
16. Preventing DVT following total knee replacement: a review of recent clinical trials.
Fitzgerald RH
Orthopedics; 1995 Jul; 18 Suppl():10-1. PubMed ID: 7479418
[TBL] [Abstract][Full Text] [Related]
17. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
Fitzgerald RH; Spiro TE; Trowbridge AA; Gardiner GA; Whitsett TL; O'Connell MB; Ohar JA; Young TR;
J Bone Joint Surg Am; 2001 Jun; 83(6):900-6. PubMed ID: 11407799
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review.
Rashki Kemmak A; Abutorabi A; Alipour V
Clin Drug Investig; 2020 Aug; 40(8):715-725. PubMed ID: 32578155
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty.
Wade WE; Hawkins DW
Orthopedics; 2000 Apr; 23(4):335-8; discussion 338-9. PubMed ID: 10791583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
